Physician profile
Lesley A Sutherland
NPI 1275953309
$5,775.22
in general payments reported to CMS, 2019-2025
37 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $261 · 2021: $123 · 2022: $217 · 2023: $573 · 2024: $1,667 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,028 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,027.91 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.94 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $596.68 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $371.71 | 2019-2025 | |
| Organon LLC | $305.87 | 2025 | Vtama, Nexplanon |
| Ucb, INC. | $297.98 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $279.09 | 2023-2024 | Vtama |
| Lilly USA, LLC | $274.22 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $274.16 | 2019-2024 | Dupixent |
| Amgen INC. | $270.15 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $223.01 | 2019-2024 | |
| Pfizer INC. | $219.06 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $218.52 | 2024 | Ycanth |
| Incyte Corporation | $214.60 | 2023-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $203.33 | 2019-2025 | Blu-U, Odomzo |
| Arcutis Biotherapeutics, INC. | $160.02 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $140.56 | 2022-2025 | Sotyktu |
| Celgene Corporation | $135.75 | 2019 | |
| Strata Skin Sciences, INC. | $129.24 | 2023-2025 | Xtrac |
| Galderma Laboratories, L.P. | $127.95 | 2019-2025 | Nemluvio, Aklief |
| Mimedx Group, INC. | $109.74 | 2024 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Almirall LLC | $58.84 | 2019-2024 | Seysara |
| Biofrontera INC. | $53.87 | 2019-2025 | |
| Leo Pharma INC. | $45.25 | 2024-2025 | Adbry |
| Revance Therapeutics, INC. | $33.57 | 2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.51 | 2024 | Spevigo |
| Convatec INC. | $32.98 | 2024 | |
| Mayne Pharma Commercial LLC | $25.55 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.25 | 2024 | Cabtreo |
| Ets Wound Care LLC | $22.53 | 2024 | Mirragen Advanced Wound Matrix |
| Vyne Pharmaceuticals INC. | $19.83 | 2020 | |
| Genentech USA, INC. | $18.50 | 2019 | |
| Lnhc, INC | $17.78 | 2025 | Zelsuvmi |
| Aclaris Therapeutics, INC. | $17.01 | 2019 | |
| Epi Health, LLC | $12.32 | 2019 | |
| Glenmark Therapeutics INC. | $12.00 | 2019 | |
| Mission Pharmacal Company | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.